seen from France
seen from Germany
seen from United States
seen from China
seen from Ukraine
seen from China
seen from Russia
seen from Canada
seen from Malaysia
seen from China
seen from Sweden
seen from China
seen from Russia
seen from United States
seen from France
seen from United States
seen from Sweden
seen from Germany
seen from United States
seen from United States
Medical Device Consultancy - We support all medical device organisations, from start-ups to multinational organisations, with cost-effective regulatory solutions. We have experts from the computer field to support Software as a Medical Device (SaMD), Biomedical Engineers with medical device knowledge and industry experience.
https://omcmedical.com/
Die Schweizer Heilmittelbehörde „Swissmedic“ in Bern veröffentlichte Zahlen zu den Nebenwirkungen der beiden in der Schweiz verwendeten mRNA-Impfstoffe von Pfizer/BioNTech und Moderna. Die eigentliche Brisanz zeigt sich allerdings erst im Vergleich mit einem „normalen“ Impfjahr wie 2019.
Die Schweizer Heilmittelbehörde „Swissmedic“ in Bern veröffentlichte Zahlen zu den Nebenwirkungen der beiden in der Schweiz verwendeten mRNA-Impfstoffe von Pfizer/BioNTech und Moderna. Die eigentliche Brisanz zeigt sich allerdings erst im Vergleich mit einem „normalen“ Impfjahr wie 2019.
Die Schweizerische Zulassungs- und Aufsichtsbehörde für Arzneimittel und Medizinprodukte, Swissmedic, hat die Zulassung des Corona-mRNA-Impfstoffes abgelehnt. In Großbritannien ist der Impfstoff von BioNTEch und Pfizer...
Die Schweizerische Zulassungs- und Aufsichtsbehörde für Arzneimittel und Medizinprodukte, Swissmedic, hat die Zulassung des Corona-mRNA-Impfstoffes abgelehnt. In Großbritannien ist der Impfstoff von BioNTEch und Pfizer...
swissmedic a réagi à votre billet :@swissmedic NOT SPAM I SWEAR. it seems to be...
OH YEAH? THEN WHAT DOES THIS IMAGE SAY, HUH?? [img of garbled captcha] KATE??? OR SHOULD I SAY UNIT #20381329???!
NO HOW DARE U THWART ME AND WITH THAT UNREADABLE IMAGE
Swissmedic Approves Xadago® (Safinamide) for Use in Parkinson's Disease
We keep on working to ensure this new chemical entity will be available to all the patients in need of innovative therapies in Parkinson's Disease." Stefan Weber, CEO of Newron, added: "We are delighted that PD patients in Switzerland will now have ... Read more at http://parkinson.healthcrisis.info/?p=8557
Vacina experimental contra o ébola começa a ser testada na Suíça
Vacina experimental contra o ébola começa a ser testada na Suíça
A Swissmedic, agência que regula produtos terapêuticos, começou a testar o medicamento esta terça-feira, 28, em 120 pessoas. Neste momento, decorrem também outros testes no Mali, Reino Unido e EUA.
A Organização Mundial de Saúde (OMS), com sede em Genebra, precisou que os reguladores suíços autorizaram o início dos testes desta vacina experimental, desenvolvida pela empresa britânica…
View On WordPress
